• Users Online: 279
  • Home
  • Print this page
  • Email this page
Home About us ASMR Conference Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 12  |  Issue : 1  |  Page : 6-12

Histopathological and immunohistochemical study of matrix metalloproteinase-2 and matrix metalloproteinase-9 in breast carcinoma


1 Department of Pathology, Division of Medical, National Research Centre, Giza, Egypt
2 Department of Pathology, Faculty of Medicine, Cairo University, Giza, Egypt

Correspondence Address:
Marwa El-Araby Shabana
Reasercher at NRC, Department of Pathology, Division of Medical, National Research Centre, Al Bouhouth Street, Dokki, Giza
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1687-4293.208860

Rights and Permissions

Background/aim Breast cancer is the most harmful tumor among women around the world, with increasing incidence rates. Invasion and metastasis are the most insidious and life-threatening parts of the cancer. Efforts have been made to understand the mechanisms that regulate and facilitate the metastatic process. This step in metastasis of malignant cells requires the association of proteolytic catalysts that degrade protein segment of the extracellular matrix. Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) are the members of degrading enzymes required in tumor advancement, invasion, and metastasis. This work aims to examine the utility of MMPs in breast carcinoma to assess their usefulness in growth, invasion, and metastasis. Patients and methods A total of 60 samples of cases of breast cancer with positive and negative lymph nodes were collected randomly as paraffin blocks which was previously prepared material. The samples from the cases were immunostained for MMP-2 and MMP-9, and their expression was correlated with various clinicopathological parameters. Results Most cases of cancer were presented in the age group 51–60 years. The most common type was invasive duct carcinoma Not Otherwise Specified (NOS), representing 70% of cases. Overall, 51 (85%) cases were positive for MMP-2 whereas 54 (90%) cases were positive for MMP-9. Presence of MMP-2 and MMP-9 in peritumoral stroma was in the ratio of 60 and 64%, respectively. Both markers were significantly elevated in malignant tissues of patient with lymph node metastasis as compared with those without lymph node metastasis (P=0.029 and 0.048, respectively). The expression of MMP-2 and MMP-9 increased with advanced clinical staging and grading (P=0.015 and 0.011). Conclusion Expression of MMP-2 and MMP-9 in breast cancer is closely correlated with positive lymph node, high histological grade, and advanced clinical stage. More studies with a huge sample size are needed to assess the prognostic role of MMPs in breast cancer. The use of MMP inhibitors as an adjuvant treatment for breast carcinoma is recommended.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1398    
    Printed99    
    Emailed0    
    PDF Downloaded197    
    Comments [Add]    

Recommend this journal